Unique ID issued by UMIN | UMIN000005686 |
---|---|
Receipt number | R000003694 |
Scientific Title | Prospective, randomized, open-label,clinical trial comparing the effects of aliskiren and amlodipine on blood pressure, endothelial function and makers for obesity/oxidative stress/chronic kidney diseases |
Date of disclosure of the study information | 2011/06/01 |
Last modified on | 2013/09/12 17:25:20 |
Prospective, randomized, open-label,clinical trial comparing the effects of aliskiren and amlodipine on blood pressure, endothelial function and makers for obesity/oxidative stress/chronic kidney diseases
Prospective, randomized, open-label,clinical trial comparing the effects of aliskiren and amlodipine
Prospective, randomized, open-label,clinical trial comparing the effects of aliskiren and amlodipine on blood pressure, endothelial function and makers for obesity/oxidative stress/chronic kidney diseases
Prospective, randomized, open-label,clinical trial comparing the effects of aliskiren and amlodipine
Japan |
Hypertension
Medicine in general |
Others
NO
Comparison of aliskiren versus amlodipine on blood pressure, endothelial function and levels of markers for inflammation/obesity/oxidative stress/early stage kidney diseases.
Efficacy
Phase IV
Blood pressure (On visit/Home monitoring)
Flow-mediated vasodilation in forearm
Heparin-releasable EC-SOD levels
Eight weeks after administration
Markers indicating obesity (e.g. adiponectin), inflammation (high sensitive CRP), oxidative stress (8-OHdG/ MDA-LDL), early-staged kidney diseases (microalbuminuria)
Eight weeks after administration
Interventional
Cross-over
Randomized
Open -but assessor(s) are blinded
Active
2
Treatment
Medicine |
Administration of aliskiren
Administration of amlodipine
20 | years-old | < |
75 | years-old | > |
Male and Female
1) Hypertensive patients with no treatment or administration of antihypertensive drug except below drug, who did not reach the recommendation of Hypertension Guidelines issued by Japanese Association of Hypertension(ARB, ACE, inhibitor of rennin, CCB)
2) Outpatients
3) Subjects who gave written informed consent
1) Allergy against aliskiren/amlodipine
2) Poor-controlled hypertension (DBP>110 mmHg)
3) Poor-controlled diabetes (HbA1c>8.0 %)
4) Secondary hypertension
5) History of stroke, acute coronary syndrome or any cardiovascular diseases needed for inpatient-treatments within 6 months
6) Either level of aspartate aminotransaminase or alanine aminotransferase exceeds three-fold of the normal limits.
7) End stage renal disease
8) Symptomatic (NYHA III or IV) congestive heart failure
9) Malignancies or other diseases with poor prognosis
10) Pregnant
11) Subjects whose doctor in charge do not agree to join the trial
60
1st name | |
Middle name | |
Last name | Katsunori Ikewaki |
National Defense Medical College
Department of Internal Medicine I
3-2 Namiki, Tokorozawa, JAPAN 359-8513
04-2995-1597
katsunorike@ndmc.ac.jp
1st name | |
Middle name | |
Last name | Makoto Ayaori |
National Defense Medical College
Department of Internal Medicine I
3-2 Namiki, Tokorozawa, JAPAN 359-8513
04-2995-1597
ayaori@ndmc.ac.jp
National Defense Medical College
Foundation for Promotion of Defense Medicine
Non profit foundation
Japan
NO
防衛医科大学校
2011 | Year | 06 | Month | 01 | Day |
Unpublished
Terminated
2010 | Year | 02 | Month | 01 | Day |
2010 | Year | 02 | Month | 01 | Day |
2012 | Year | 01 | Month | 01 | Day |
2011 | Year | 05 | Month | 31 | Day |
2013 | Year | 09 | Month | 12 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003694